Bimekizumab for the treatment of psoriatic disease

References

• de Jager ME, De Jong E, Evers A, et al. The burden of childhood psoriasis. Pediatr Dermatol. 2011 Nov–Dec;28:736–737. PMID: 21692835.
   PubMed Web of Science ®Google Scholar
• Strohal R, Kirby B, Puig L. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2014;12:1661–1669. PMID:24372845.
   Google Scholar
• Kaushik SB, Lebwohl MG. CME Part I psoriasis: which therapy for which patient psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2018 Jul 11. pii: S0190-9622(18)32215–1. DOI:10.1016/j.jaad.2018.06.057.
   Google Scholar
• Mease P, Kivitz A, Burch F, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236. PMID: 15818699.
   PubMedGoogle Scholar
• González CM, Carmona L, de Toro J, et al. Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. Patient Prefer Adherence. 2017;11:1243–1252. . PMID: 28790806.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Birt J, Lin C-Y, et al. Presented at EULAR. 2018.
   Google Scholar
• Eichenfield L, Paller A, Tom W, et al. Pediatric psoriasis: evolving perspectives. Pediatr Dermatol. 2018;35:170–181.
   PubMed Web of Science ®Google Scholar
• Torres T, Romanelli M, Chiricozzi A. A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Invest Drugs. 2016;25:751–754. PMID: 27153320.
   PubMed Web of Science ®Google Scholar
• Durham LE, Kirkham BW, Taams LS. Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2015;17:55. PMID: 26209291.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK. Mechanistic rationales for targeting interleukin-17A in spondyloarthritis. Arthritis Res Ther. 2017;19:51. PMID: 28270233.
   PubMed Web of Science ®Google Scholar
• Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60.
   PubMedGoogle Scholar
• Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991–1001.
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. Embo J. 2001;20:5332–5341. PMID: 11574464.
   PubMed Web of Science ®Google Scholar
• Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205:1063–1075. PMID: 18411338.
   PubMed Web of Science ®Google Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523–532. PMID: 29275332.
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018 Mar 30. pii: S0190-9622(18)30491–2 [Epub ahead of print]. DOI:10.1016/j.jaad.2018.03.037.
   Web of Science ®Google Scholar
• Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13:54–58. PMID: 24035809.
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–1312.
   PubMed Web of Science ®Google Scholar
• Lévy R, Okada S, Béziat V, et al. Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc Natl Acad Sci U S A. 2016;113:E8277–E8285. PMID: 27930337.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Yamada M, Kawai T, et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol. 2014;193:4880–4887. PMID: 25288569.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Strand V, Kishimoto M, et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018 Oct 1;57(10):1777–1788. .
   PubMed Web of Science ®Google Scholar
• Nash P, McInnes IB, Mease PJ, et al. Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison. Rheumatol Ther. 2018;5(1):99–122.
   PubMed Web of Science ®Google Scholar